Overcoming AML Resistance: Targeting OPA1 to Restore Venetoclax Sensitivity
25th Nov 2025
Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies to treat. Venetoclax (Venclexta), a BCL-2 inhibi
25th Nov 2025